Risk reduction of progression of microvascular complications in the DCCT intensive treatment group per 50% higher C-peptide value and comparing C-peptide responders (≥0.2–5 nmol/L) versus nonresponders (<0.2 nmol/L), with no adjustments and with adjustment for the complication status and HbA_1c on entry